FDA

#Fast Track designation #FDA #Rare diseases

FDA grants Fast Track Designation to rare disease treatment 

The US Food and Drug Administration (FDA) has granted Fast Track Designation to a treatment for the rare paediatric disease late-infantile neuronal ceroid lipofuscinosis (LINCL/CLN2 disease).  PLX-200, developed by biotechnology company Polaryx Therapeutics, will now undergo an expedited review with the potential to address the paediatric disease with unmet need.  The treatment is… Read More

#News #Regulatory

pulmonary arterial hypertension
#FDA #Hypertension #nda

FDA accepts NDA for hypertension treatment option 

The US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for hypertension drug lorundrostat.  Biopharmaceutical company Mineralys Therapeutics announced the NDA for lorundrostat was accepted for the treatment of adult patients with hypertension in combination with other antihypertensive drugs. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action… Read More

#News #Regulatory

Novo Nordisk head office
#Adverse event #FDA #GLP-1 #Novo Nordisk #Obesity #Ozempic

Novo receives FDA warning, strikes deal with Hims & Hers

Novo Nordisk has received a Warning Letter from the US Food and Drug Administration (FDA) related to violations of postmarketing adverse drug experience (PADE) regulations.  The letter relates to an inspection that took place in early 2025, in which the FDA found serious violations of PADE reporting requirements, in response… Read More

#Business & Investment #News #Regulatory #Trending News

Bacteria
#Centauri Therapeutics #FDA #Gram-negative bacteria

Gram-negative bacterial infection treatment gets QIDP status 

The US Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to a novel treatment of Gram-negative bacterial infections.  CTX-187, developed by immunotherapy company Centauri Therapeutics, is a novel immunotherapeutic approach to treat Gram-negative bacterial infections. It is hoped the therapeutic, currently in preclinical development ahead of… Read More

#News #Regulatory

#Ascendis Pharma #BioIndustry Association #Cancer therapy #CHMP #Clinical trial #Diversity #European Medicines Agency #FDA #Gene therapy #Oncology #Paediatrics #Rare disease #uniQure #University of Queensland #Women in STEM

DDW Highlights: 10 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, figures showed the number of women in biotech leadership has stalled. Elsewhere, could… Read More

#Podcasts

#Advanced Therapies #FDA #Gene therapy #Huntington's disease #uniQure

Investors file lawsuit against uniQure following FDA ruling

The US Food and Drug Administration (FDA) has ruled that data from Phase I/II studies are insufficient evidence to approve the marketing authorisation for uniQure’s AMT-130, an investigational gene therapy for Huntington’s disease (HD).   In response, investors have issued a class action securities lawsuit to recover losses.  The FDA said… Read More

#Business & Investment #News #Trending News

FDA headquarters
#FDA #Haematology #Oncology #Pentixapharm #Radiopharmaceuticals

FDA approves Pentixapharm’s dual theranostic INDs

The US Food and Drug Administration (FDA) has approved a clinical study of Pentixapharm’s CXCR4-targeted theranostic programme in haemato-oncology, following a 30-day safety review of two Investigational New Drug (IND) applications.  The two IND submissions support the single PENTHERA Phase I/II protocol, which evaluates the combined use of PentixaFor imaging… Read More

#News #Regulatory

CRISPR gene editing
#Advanced Therapies #FDA #Gene therapy #Intellia Therapeutics #Phase III trial

Regulator lifts clinical hold on Intellia’s gene therapy trials

The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE Phase III clinical trial of nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).  The clinical holds on the INDs for MAGNITUDE and MAGNITUDE-2 were imposed… Read More

#News #Regulatory #Trending News

Stamp of approval
#Accelerated assessment #Ascendis Pharma #FDA #Paediatrics #Rare disease

FDA approves first once-weekly achondroplasia therapy

The US Food & Drug Administration (FDA) has granted approval for Yuviwel (navepegritide) under its Accelerated Approval Program.  Navepegritide is the only once-weekly treatment indicated to increase linear growth in children one years of age and older with achondroplasia with open epiphyses and the only one to provide continuous systemic… Read More

#News #Regulatory

Gene editing
#Advanced Therapies #Fast Track designation #FDA #Gene editing #Gene therapy #Tessera Therapeutics

In vivo gene editing programme for AATD fast-tracked by FDA

The US Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to TSRA-196, Tessera Therapeutics’ lead in vivo gene editing programme.  TSRA-196 is being jointly developed with Regeneron for the treatment of adults with alpha-1 antitrypsin deficiency (AATD) who are homozygous for the PiZ allele (PiZZ).  … Read More

#Editor's Choice #News #Regulatory

Stem cell transplant
#Biologics License Application (BLA) #Clinical trial #FDA

FDA accepts BLA for kidney transplant drug imlifidase

The US Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for a drug desensitising highly sensitised adult kidney transplant patients.  Imlifidase, developed by biopharmaceutical company Hansa Pharma, is a unique IgG cleaving enzyme that rapidly inactivates over 95% of donor-specific antibodies within two to six hours of administration, providing a crucial… Read More

#News #Regulatory

#ABPI #Biomanufacturing #Cancer research #Clinical trial #Diabetes #European Union #FDA #Fujifilm #Oncology #Priority Review #Rare diseases #RNA #UK

DDW Highlights: 17 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers made a key discovery into cancer survival. Elsewhere, a global research effort… Read More

#Podcasts

#ABPI #Biomanufacturing #Cancer research #Clinical trial #Diabetes #European Union #FDA #Fujifilm #Oncology #Priority Review #Rare diseases #RNA #UK #United States

This week in Drug Discovery (9 – 13 February) 

News round-up for 9 – 13 February by Bruno Quinney, Content Team at DDW.  This week in DDW, researchers have made a key discovery into cancer survival. Elsewhere, a global research effort into kidney disease is underway.  The top stories:    Researchers identify RNA linked to cancer… Read More

#News

#Drug development #Emulate #FDA #SLAS2026

Emulate showcases organ-chip platform at SLAS2026 

Emulate has brought its AVA Emulation System to SLAS2026, showcasing the potential to accelerate drug development with a first-of-its-kind high-throughput organ-chip platform.  The AVA Emulation System, launched in June 2025, is a self-contained instrument that cultures, incubates, and images up to 96 independent organ-chip samples in… Read More

#News

#Alzheimer's #Bacteria #Brain cancer #Cancer immunotherapy #Clinical trial #Drug resistance #Fast Track designation #FDA #Gene therapy #Life sciences #Melanoma #Siren Biotechnology #UK government #University of Sydney

DDW Highlights: 10 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative therapies showed the way to more effective cancer treatments. Elsewhere, how can… Read More

#Podcasts

#FDA #Priority Review #Rare diseases #SynaptixBio

US Senate reauthorises Priority Review Voucher scheme 

The US Senate has reauthorised the US Food and Drug Administration (FDA)’s Priority Review Voucher (PRV), helping biotech companies to develop rare disease drugs.  The PRV programme, which incentivises rare disease drug development, was reauthorised on 30 January, with President Donald Trump signing the bill.  On 1 December last year, the House of Representatives passed… Read More

#News #Regulatory